|
|
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Trusts (England) - Medical Director
|
|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Foundation Trusts (England) - Chief Executive
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Director of Public Health
- NHS Trusts (England) - Chief Executive
- GP - Locum
- NHS 111 and Out of hours providers
- Dispensing GP Practices
- GP Practices
- DHSC Supply Disruption - Medicines
- Primary Care Networks
|
| Title: |
|
CLASS 4 DRUG ALERT, FOR INFORMATION, TENOLOL LIMITED (MA HOLDER) / DRUGSRUS LTD (DISTRIBUTOR), DEPO-PROVERA 150MG/ML INJECTION
|
| Broadcast content: |
|
Drugsrus Ltd
(distributor) / Tenolol Ltd (MA Holder) have informed us of a typographical
error for the active ingredient stated on the label on the vial. The active
ingredient should be “medroxyprogesterone acetate” (a long acting
contraceptive) however, it is stated as “methylpredinisolone acetate” (a
corticosteroid) in error. The batches are not
being recalled, as there are no concerns with the quality, safety and efficacy
of the product. Existing stock at Drugsrus Ltd has been quarantined and no new
stock will be released with the affected issue. Full details of the drug alert are included in the attached PDF file. Please forward to listed recipients. This information is also published on the MHRA website https://www.gov.uk/drug-device-alerts. |
|
| Additional information: |
|
NHS England Regional Offices: Please cascade this alert to any Community Pharmacy and Dispensing GP Practices yet to be registered with CAS.
GP Practices: Please note this alert is for Dispensing GP Practices only.
|
| Cascade to: |
|
- #COMMUNITYPHARMACISTS#
- #DISPENSING GP#
- #HospitalPharmacy#
|